VascuFlex® 5 and 6 F

Peripheral self-expanding nitinol stent system

Percutaneous transluminal angioplasty (PTA) and stenting of the superficial femoral and popliteal arteries is the proposed treatment of choice in the majority of patients with intermittent claudication (IC) or critical limb ischemia (CLI) on the basis of its reduced perioperative morbidity and mortality, and reduced in-hospital stay [1, 2]. To date, several new technologies, such as self expanding bare metal stents made from nitinol and drug-coated balloons (DCB), have emerged with the aim to improve long-term patency outcomes following angioplasty of the femoral and popliteal arteries [3, 4].

VascuFlex® 5 and 6 F is a self-expanding stent system indicated for lower extremity peripheral artery disease whose anatomical dimensions correspond to the available stent sizes.


Stent design

  • Open cell design for high flexibility and good vessel adaption
  • Minimal foreshortening
  • Excellent stent visibility with laser-welded tantalum markers

Proven delivery system

  • ePTFE lining for smooth, controlled and precise stent release (confirmed in user tests)
  • Excellent flexibility und pushability [5]
  • Radiopaque platinum markers for enhanced visibility
  • Braided shaft for high kink resistance [5]

Wide product range

  • 5F and 6F delivery systems
  • 5-10 mm stent diameters
  • 20-200 mm stent lengths
  • 80 cm, 120/130 cm shaft lengths
  • 180 cm shaft length for transradial/transbrachial approach

[1] Tendera M, Aboyans V, Bartelink ML et al (2011) ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 32(22):2851–2906

[2] Tsetis D, Belli AM (2004) Guidelines for stenting in infrainguinal arterial disease. Cardiovasc Intervent Radiol 27(3):198–203

[3] Cassese S, Byrne RA, Ott I et al (2012) Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv 5(4):582–589

[4] Schillinger M, Sabeti S, Loewe C et al (2006) Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 354(18):1879–1888

[5] Data on file at B. Braun